6th Annual Biopharma Development and Production Week China 2020

China’s biologics market continues to aggressively expand and achieve greater heights – regulatory reforms, new investments into the biopharma sector, more international partnerships coming into place and local biopharmas looking to go global. Product innovation and investment opportunities are in abundance as China leads the way as the 2nd largest biologics market in the world.
 
With numerous shifts on the horizon, the Chinese industry approaches a tipping point as companies reevaluate current trends and strategies to achieve commercial excellence. The 6th iteration of BDP Week will address the 2020 investment climate, technological advancements, industry case studies, and partnerships and expansion opportunities across key value chains.
 
With improved networking windows and elevated exhibition platforms, join us as the industry convenes at this highly anticipated annual gathering of biopharma leaders.
 

AGENDA AT-A-GLANCE

 

Tue, 3 November 2020
Day 1 of Main Conference
 
KEYNOTE ADDRESS
China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization
China’s Biological Facilities for the Future – WuXi’s Story on Technology & Innovation

 
* Biomanufacturing 2030 – the hottest shifts in manufacturing in China
* Trends in Pharma 4.0 standards and China’s new drug delivery strategy
* Industry case studies for commercial manufacturing
* The state-of-play for cell line development
* Applications for furthering biopharma R&D strategy
* Novel CLD platform technologies and tools
* Industry case studies for high-throughput screening and performance
* Maneuvering the Chinese Market for Cell and Gene Therapies
* Addressing the next wave of innovations in cell therapies
 

Wed, 4 November 2020
Day 2 of Main Conference
Manufacturers’ Panel: New Therapies, New Tech & New Investments

 
* Smarty biomanufacturing and process optimization
* Manufacturing technology showcases – Improving cost and efficiency
* Innovative bioprocess development
* Sustainable manufacturing and scalability
* Advancements in cell engineering techniques for complex proteins
* CRISPR and genomics in focus
* Data-driven, accelerated, and next-generation CLD
* Industry Panel: Perspectives on utilising platform technologies for CLD
* Managing cost and accelerating manufacturing process
* Latest CAR T-cell technology developments
* Facilities design and construction call therapies
 

Wed, 5 November 2020
Day 3 of Main Conference
KEYNOTE ADDRESS
China’s Biopharma Capital Markets – Future Funds & Innovative Financing
Venture Capitals Roundtable: Show Me the Drug

 
* DAL’s New GAMP and Licensing Law – Implementation and oversight
* QbD and Quality Matrix for meeting regulatory requirements
* Biomanufacturing process validation and quality risk management
* Best practices and strategies in biopharma supply chain integration
* Optimising workflows and bioprocesses
* Exploring the synergies between engineered host cells and process development for commercial success
* Industry Panel: what’s next in the future of CLD&E
* Investment and commercialisation landscape
* Case studies on clinical trial landscapes and efficacy evidence

Contact us:
Miki Kong
+6565082477
miki.kong@informa.com
Conference website: https://www.biopharmaproduction.com/?utm_source=BDP-China-2020-MP&utm_medium=referral&utm_campaign=BDP-China-2020